Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Pravachol Use Among Rx Patients Needs More Study, FDA Cmte. Says

Executive Summary

The reason individuals switch from taking prescription cholesterol-lowering agents to OTC Pravachol (pravastatin) in actual use studies should be the subject of additional research, FDA advisory committee members suggested to Bristol-Myers Squibb July 14.
Advertisement

Related Content

Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP
Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP
Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA
Bristol Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Bristol Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Advertisement
UsernamePublicRestriction

Register

PS036382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel